INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a progressive disease where hyperglycemia occurs when insulin secretion fails to keep pace with insulin resistance. 1 Therefore, long-term disease management warrants intensification of treatment over time, especially in step with declining beta-cell function. 2 In general, and thiazolidinediones [TZD] ) and insulin are associated with weight gain, which can compromise patients' ongoing attempts at weight reduction. 4 At the point of introducing exogenous insulin, depending on national guidelines and individual preferences, OADs other than metformin are often discontinued.
The ultimate level of intervention is to add mealtime bolus insulin to, typically, basal insulin plus metformin, or to substitute a premixed insulin regimen.
Over the last few years we have seen the advent of newer drugs in the form of incretinbased therapies. These act primarily by increasing the physiological effects mediated via the hormone glucagon-like peptide-1 (GLP-1), which is secreted along with glucosedependent insulinotropic polypeptide (GIP) by intestinal cells when food is ingested, probably via the neural and endocrine signals associated with feeding. 5 GLP-1 and GIP have multiple actions that enhance beta-cell response in a glucose-dependent fashion. In T2DM, the incretin response is diminished. 6 However, the insulinotropic action of GIP is diminished, while that of GLP-1 is preserved, although the secretion of GLP-1 appears to be diminished. 7, 8 Nevertheless, as the tissue sensitivity to GLP-1 is preserved 7, 9 (Table 1) . 7, [10] [11] [12] [13] [14] [15] [16] [17] From a blood glucose-lowering point of view, the most appealing property is that GLP-1 glucose dependently increases insulin secretion and suppresses glucagon secretion.
Therefore, these actions manifest only in the setting of hyperglycemia. Moreover, counterregulatory responses to hypoglycemia (including glucagon secretion) are fully preserved, even when pharmacological levels of GLP-1 are administered. 18 In addition, GLP-1 induces satiety and has weight limiting effects, 13, 19, 20 along with potential beta-cell sparing actions. 15, 16 DPP-4 inhibitors (incretin enhancers) are orally available drugs that are weight neutral
Summary of pancreatic and extra-pancreatic effects of glucagon-like peptide-1 in humans.
Glucose-dependent stimulation of insulin secretion 7 Glucose-dependent suppression of glucagon secretion 7 Enhanced glucagon secretion during hypoglycemia 10, 11 Reduced gastrointestinal motility and pancreatic exocrine function 12 Increased satiety 13 Improvement of beta-cell function 14 Increased beta-cell mass with inhibition of beta-cell apoptosis [15] [16] [17] Even though incretin enhancers and mimetics act through the same therapeutic axis, their overall drug profile varies (Table 2) . Hence, these differences offer a unique role for each of the drug groups in the treatment algorithm for T2DM.
SAFETY AND ADVERSE EVENTS WITH INCRETIN BASED THERAPY
The most common side effect with GLP-1RA is nausea and, occasionally, vomiting. The frequency of gastrointestinal adverse events is less pronounced with DPP-4 inhibitors.
Generally symptoms diminish over time. trial compared once weekly exenatide against glargine. 30 In this while beta-cell function is preserved. There is also evidence from in vitro and animal studies that these agents could preserve beta-cell mass and function, and hence, potentially slow or halt disease progression. 16, 17 Moreover, there is increasing interest in using the incretins in combination with exogenous insulin therapy.
The next section reviews the potential clinical role of such regimens, given the pathophysiology of T2DM.
Future Role For Incretin Therapy
Hyperglycemia in T2DM typically manifests initially as elevated postprandial glycemia (PPG), followed by fasting hyperglycemia. 32, 33 Furthermore, postprandial insulin secretion is greatly influenced by the incretin system, and the incretin system appears to be impaired in T2DM. Moreover, glucagon secretion is inappropriately elevated in T2DM.
Hence, hepatic glucose output is increased, contributing to both postprandial and fasting hyperglycemia. 34, 35 
Clinical Evidence Supporting Adding

Incretin-Based Therapies to Basal Insulin
Recent clinical studies allude to the advantage of adding incretin-based therapies to basal insulin, especially in terms of offsetting the associated weight gain as well as the reduction or neutrality in incidence of hypoglycemia. [50] [51] [52] [53] [54] [55] These effects are observed even when incretinbased therapies are added at a relatively later stage of disease. There have also been some studies assessing insulin added to incretin-based therapies. 56, 57 Data from these studies, albeit limited, demonstrates that a Potentially delay or avert the need for insulin
Low risk of hypoglycemia in comparison to insulin therapy
Weight gain associated with insulin initiation might be minimized by established incretin therapy Tolerance to nausea is established before insulin is introduced Table 4 . Benefits of introducing incretin therapy before establishing patients on insulin.
GLP-1RA can continue to make a major contribution to glucose lowering once insulin is introduced and supports yet another theoretically appealing treatment approach (Table 4) .
O n t h e o t h e r h a n d , t h e r e a r e pathophysiological and pharmacological arguments for introducing incretin therapies early in the disease process before insulin is 66 The prospect of prolonged use of incretin therapies also requires us to study the long-term safety profiles of these agents and regimens. 
